Pharmaceutical API and Formulation Market Set to Expand as Chronic Disease, Aging and Advanced Manufacturing Reshape Drug Supply

The global Pharmaceutical API and Formulation Market is entering a sustained expansion phase as pharmaceutical manufacturers respond to rising healthcare demand, an aging population and the growing burden of chronic diseases. According to Next Move Strategy Consulting, the market was valued at USD 217.24 billion in 2024 and is projected to reach USD 326.12 billion by 2030, representing a 7.0% compound annual growth rate (CAGR) from 2025 to 2030. The outlook reflects increasing demand for active pharmaceutical ingredients (APIs), finished formulations and specialized manufacturing capabilities across major therapeutic categories.

View the

Pharmaceutical API and Formulation Market report from Next Move Strategy Consulting

Request the FREE Sample Here

Market Growth and Outlook

APIs are the biologically active components responsible for the therapeutic effect of medicines, while pharmaceutical formulations convert those ingredients into usable dosage forms such as tablets, capsules, liquids and semi-solids. The combined market therefore sits at the center of pharmaceutical production, spanning ingredient synthesis, biological manufacturing, formulation development and commercial drug manufacturing.

Next Move Strategy Consulting identifies 2024 as the base year, with the forecast covering 2025–2030. From the 2024 value of USD 217.24 billion, the market is expected to add more than USD 100 billion in annual value by 2030 as demand for medicines expands and pharmaceutical companies invest in production capacity, research and development, and increasingly sophisticated manufacturing technologies.

The underlying demand is reinforced by global healthcare needs. The World Health Organization and the International Agency for Research on Cancer reported almost 20 million new cancer cases in 2022, with annual cases projected to reach approximately 35 million by 2050. A larger chronic disease burden creates continuing requirements for therapies and, consequently, the APIs and formulations needed to manufacture them.

Key Market Drivers

Rising chronic disease prevalence remains one of the most important structural drivers. Next Move Strategy Consulting identifies cancer and other chronic conditions as sources of sustained pharmaceutical demand. Oncology, cardiovascular, diabetes, respiratory and central nervous system therapies all require broad ranges of active ingredients and finished dosage forms.

Population aging is another long-term catalyst. The market report notes that the proportion of people aged 65 and above is projected to increase globally, while age-related disorders such as cardiovascular disease, diabetes and neurodegenerative conditions create greater demand for pharmaceutical treatment.

Rising healthcare expenditure is supporting investment across the pharmaceutical value chain. Greater healthcare spending can expand access to medicines while encouraging pharmaceutical manufacturers to strengthen research, development and production capabilities. Next Move Strategy Consulting specifically identifies higher healthcare expenditure as a principal market growth factor.

Supply-chain resilience and domestic manufacturing are also becoming strategic priorities. India, for example, has implemented production-linked incentives for critical key starting materials, drug intermediates and APIs, with government programs designed to strengthen domestic production and reduce dependence on imported pharmaceutical inputs.

Emerging Market Trends

One of the strongest technology trends is the growing use of artificial intelligence in drug and API development. Next Move Strategy Consulting identifies AI-enabled API synthesis as a major opportunity, noting its potential to improve prediction of drug efficacy and adverse effects and shorten elements of the development process.

The move toward advanced pharmaceutical manufacturing is also accelerating. The U.S. Food and Drug Administration’s current advanced-manufacturing framework prioritizes technologies including end-to-end continuous manufacturing, distributed manufacturing, point-of-care manufacturing and artificial intelligence in manufacturing. The agency says these approaches can support improvements in drug production while maintaining product quality.

Another trend is the increasing importance of high-potency and biologic APIs. The Next Move Strategy Consulting report separately identifies synthetic APIs, biotech and biological APIs, and high-potency APIs as key market categories. Biological ingredients include monoclonal antibodies, recombinant proteins and peptides, reflecting the growing diversity of modern pharmaceutical pipelines.

Contract development and manufacturing organizations (CDMOs) are also becoming increasingly relevant to pharmaceutical supply strategies. The market study distinguishes between captive in-house API manufacturing and merchant manufacturing provided by third parties and CDMOs, highlighting the role of outsourcing within the broader pharmaceutical production ecosystem.

At the same time, regulatory complexity remains a constraint. Clinical trials, stability testing, post-market surveillance and approval requirements can extend development timelines and raise the cost and operational complexity of introducing new API and formulation products.

Regional Analysis

North America is identified by Next Move Strategy Consulting as the dominant regional market during the forecast period. The region benefits from an established pharmaceutical industry, significant healthcare demand and extensive capabilities across drug development, API production and formulation manufacturing.

Asia-Pacific also remains strategically important, with the study covering major pharmaceutical production and consumption markets including China, Japan, India, South Korea, Australia and Southeast Asia. India is particularly significant because government initiatives are encouraging domestic production of critical pharmaceutical inputs and strengthening the country’s manufacturing base.

Europe, meanwhile, remains an important pharmaceutical manufacturing and regulatory center, with the market study covering major countries including the United Kingdom, Germany, France, Italy, Spain and several Nordic markets. The breadth of regional coverage reflects the increasingly international nature of API sourcing and finished-drug manufacturing.

Industry and Competitive Landscape

The competitive environment includes major pharmaceutical and healthcare companies such as Pfizer, Merck & Co., Cipla, Novartis, Dr. Reddy’s Laboratories, Johnson & Johnson, Mankind Pharma, AbbVie, Bristol Myers Squibb, Lupin Pharmaceuticals, Alkem Laboratories, Bayer, Amgen, GSK and Abbott Laboratories, according to the Next Move Strategy Consulting report.

Competition is increasingly shaped by manufacturing scale, formulation expertise, specialized APIs, supply reliability and technology investment. Companies are also pursuing expansion and collaboration strategies to strengthen production capabilities and respond to changing pharmaceutical demand. The broader industry is simultaneously under pressure to maintain quality and continuity of supply, with the U.S. FDA noting that manufacturing and quality problems, delays and discontinuations can contribute to drug shortages.

“The pharmaceutical API and formulation market is being shaped by a combination of rising therapeutic demand and a fundamental shift in how medicines are developed and manufactured. AI-enabled research, advanced production technologies and greater attention to supply resilience are creating new opportunities, while regulatory complexity continues to require substantial investment and technical expertise,” said a spokesperson at Next Move Strategy Consulting.

Market Report Overview

The Pharmaceutical API and Formulation Market report by Next Move Strategy Consulting provides quantitative analysis and forecasts for 2025–2030, including market size, CAGR, drivers, restraints, opportunities, technology trends, regional developments and competitive analysis. The study segments the market by API type, API manufacturing type, API application, formulation type, end-user and region. API categories include synthetic, biotech/biological and high-potency APIs; manufacturing is divided between captive and merchant production; and formulations cover solid, liquid and semi-solid dosage forms. Applications span cardiovascular, oncology, anti-infective, diabetes, CNS and respiratory APIs, among others.

About Next Move Strategy Consulting

Next Move Strategy Consulting is a market research and consulting company providing market intelligence, industry analysis, competitive insights, and strategic research across a wide range of industries and geographic markets.

With the market projected to reach USD 326.12 billion by 2030, developments in chronic disease treatment, biologics, high-potency ingredients, AI-enabled drug development and advanced manufacturing will remain important areas to watch. Pharmaceutical companies, API manufacturers, CDMOs, investors, technology providers and policymakers can benefit from closely monitoring these shifts as the global medicines supply chain evolves.